Switch to:
Also traded in: Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

» ELN's 10-Y Financials

Financials (Next Earnings Date: 0)

Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ELN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )



Valuation & Return


More Statistics

Revenue(Mil) $357
EPS $ 4.62
Short Percentage of Float0.00%

Business Description

Industry: Biotechnology » Biotechnology
Traded in other countries:EAN.Germany, 0M2W.UK,
Elan Corp PLC, an Irish public limited company, is a neuroscience-based biotechnology company. It was incorporated as a private limited company in Ireland in December 1969 and became a public limited company in January 1984. It is a neuroscience-based biotechnology company and its business is organized into two business units namely BioNeurology and Elan Drug Technologies (EDT). On September 16, 2011, it announced the completion of the merger between Alkermes, Inc. and EDT. In BioNeurology, the company is developing therapies for serious diseases that have long been considered intractable, including MS, Alzheimer's disease and Parkinson's disease. EDT develops and manufactures pharmaceutical products that deliver clinically meaningful benefits to patients, using its experience and proprietary drug technologies in collaboration with pharmaceutical companies. Tysabri, a treatment for relapsing forms of MS, competes mainly with Avonex, Betaseron(r), Berlex. The pharmaceutical industry is subject to significant regulation by international, national, state and local governmental regulatory agencies.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)